Raymond A. Huml

Experience

• 

  IQVIA

  Mar 1999 - Apr 2020

  Promoted to become the Head of the Global Biosimilars Center of Excellence. Grew the biosimilar business by greater than 150% of biosimilar sales targets/year for three years in a row. Member of the biosimilar teams that garnered two parternships in Asia Pacific each worth more than $100m in new business. Served as a senior advisor to the Rare Disease and Cell & Gene Therapy Centers of Excellence.Led the strategic development and implementation of the NeuroMuscular ObserVational Research (MOVR) Data Hub at the Muscular Dystrophy Association (MDA). Spearheaded initiatives that integrated advanced data collection and analysis platforms, enhancing clinical management and drug development for neuromuscular diseases. Supported more than $200m worth of rare disease opportunities. Show less Selected from the Center for Integrated Drug Development (CIDD) to start the Global Biosimilars Unit (GBU) to develop and implement an end-to-end biosimilar business solution for clients developing biosimilar products in the global marketplace. During the first year, helped the team achieve 170% of its yearly sales target, and, as a result, the GBU was upgraded to a "Center of Excellence."Developed a strong interest in rare diseases, leading to collaboration with IQVIA's Rare Disease Center of Excellence. Contributed to the review of over $100m in Requests for Proposals (RFPs), aiding in bid defense preparations and delivering solutions for clients with rare and orphan candidates in their pipelines. Show less Selected by Quintiles CEO, Thomas Pike, to work on strategic drug development, project management of clinical trials, due diligence, forecasting analytics and database simulations. Supported NovaQuest Pharma Opportunities Fund III, LP through the formation of virtual due diligence teams comprised of Quintiles colleagues and external experts selected by NovaQuest. Led the cross-functional due diligence teams that resulted in >$250m in capital committed to multiple partnerships. From promotion to Executive Financial Director until I became Head of Global Due Diligence, I managed over 200 due diligence teams, securing almost $3B in capital commitments to biopharmaceutical partnerships of all sizes. I served as a Project Leader primarily within Corporate Development with responsibility of managing all aspects of the due diligence process, including research and development (R&D), commercial, intellectual property, legal, and conflict of interest. Managing the technical component of the due diligence process and summarized the R&D as well as commercial product risks associated with product-based investments required:· Identifying resources and assembling global teams consisting of US and international specialists (e.g., physicians, regulatory professionals, preclinical experts, pharmacologists, toxicologists, CMC experts, commercial experts and sales forecast analysts)· Prepping team members selected for the due diligence exercise on aspects of the opportunity pertinent to their disciplines· Collaborating with prospective partners, potential investors, and patent attorneys· Helping with the sales analytics and forecasting exercises· Helping with the statistical and financial modeling exercises· Summarizing technical and commercial risks associated with product-based investments in the US, EU and Japan· Helping shape the terms of the ultimate transaction (e.g., deal term sheet through contracting stages). Show less

  • Vice President of Therapeutic Strategy & Head of the Biosimilars Center of Excellence

    Jul 2019 - Apr 2020

  • VP of Therapeutic Strategy & Head of Global Biosimilars Strategic Planning and Development

    Dec 2015 - Apr 2020

  • Executive Financial Director & Head of Global Due Diligence

    Mar 1999 - Dec 2015
• 

  North Carolina State Unversity

  Sept 2013 - Mar 2021

  Member, Board of Visitors

  As a dedicated alumnus of North Carolina State University's College of Veterinary Medicine, I proudly served on the Board of Visitors from 2013 to 2017. During this tenure, I represented the College of Veterinary Medicine, contributing to the advancement of veterinary education and research at my alma mater. My role involved collaborating with fellow board members to support strategic initiatives that enhanced the college's mission of equipping future leaders. I remain passionate about fostering a strong connection between the university and its alumni. Show less

• 

  Syneos Health Clinical Solutions

  Jul 2020 - Sept 2024

  Vice President of Medical and Scientific Strategy & Head of the Rare Disease Consortium

  Leading the Rare Disease Consortium covered all of the operational and scientific aspects involved in the clinical development and commercialization for rare diseases. Provided advice and consultation, developed and presented scientific business content to advance the company's scientific reputation, brand equity, corporate growth strategy, and overall mission to better integrate the R&D and commercial portions of the business.As the inaugural executive sponsor and founder, I established and supported the Disability Employee Resource Group. Show less